BofA cuts Merit Medical stock price target on deal dilution By Investing.com

Merit Medical Systems posted a solid Q1 beat, with revenue of $382 million topping consensus by about $4 million and EPS of $0.94 beating by $0.11. Operating margin reached 19.7%, 180 basis points above expectations, and full-year revenue guidance was raised by $3 million to $1.612 billion-$1.634 billion, though EPS guidance was merely reiterated at $4.01-$4.15 after absorbing 5 cents of View Point deal dilution. BofA cut its price target to $80 from $100 while keeping a Neutral rating.

Analysis

The setup is less about the quarter itself and more about the gap between operating execution and market positioning. A company trading near lows after a clean beat with margin upside creates a classic post-earnings reset: the next leg depends on whether the Street starts underwriting a higher durable margin base rather than treating the quarter as a one-off. The fact that guidance was only modestly lifted despite the beat suggests management is intentionally preserving flexibility, which often leaves room for an incremental estimate cycle over the next 1-2 quarters.

The key second-order effect is that the core franchise appears to be doing enough to offset deal dilution and still expand earnings, which should matter more to long-only healthcare investors than the headline price-target cut. That makes MMSI a relative winner versus lower-quality medtech names that are still buying growth at the expense of margin. If the integration burden from the acquired asset stays contained, the market may re-rate the stock on the combination of organic growth plus margin resilience, not absolute revenue growth alone.

The main risk is timing: shares can stay depressed if the market focuses on cautious forward commentary and the company’s habit of under-communicating early in the year. The bigger downside catalyst would be any evidence that the reported margin strength was pull-forward, or that the deal dilution expands beyond initial expectations. Conversely, if second-quarter commentary confirms the first-quarter margin level as sustainable, the stock can likely recover over a multi-month horizon rather than needing a macro backdrop.

Key Decisions for Investors

• Go long MMSI on weakness over the next 1-2 weeks, targeting a 10-15% rebound over 2-3 months if Q2 commentary validates margin durability; use a tight stop below the recent 52-week low to limit downside if the market rejects the beat.
• Pair trade: long MMSI / short a lower-margin medtech peer with similar revenue growth but weaker operating leverage for 1-2 quarters; the trade benefits if investors reward earnings quality over raw top-line growth.
• For options, buy 3-4 month call spreads in MMSI rather than outright calls; the thesis is an incremental re-rating after Q2, not an immediate squeeze, so defined risk is preferable.
• If you already own MMSI, hold through Q2 but trim into any sharp rally before the next guidance update; the stock likely needs one more confirmation point before the market fully prices the margin step-up.